Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

11/12/24 10:32:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NUVB alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 NUVATION BIO INC CLASS A COMMON STOCK Cusip #67080N101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #67080N101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 29,235,924 Item 6: 0 Item 7: 29,238,871 Item 8: 0 Item 9: 29,238,871 Item 11: 8.759% Item 12: HC Cusip #67080N101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 29,238,871 Item 8: 0 Item 9: 29,238,871 Item 11: 8.759% Item 12: IN Item 1(a). Name of Issuer: NUVATION BIO INC Item 1(b). Address of Issuer's Principal Executive Offices: 357 TEHAMA STREET, FLOOR 3 SAN FRANCISCO, CA 617-401-9975 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: CLASS A COMMON STOCK Item 2(e). CUSIP Number: 67080N101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 29,238,871 (b) Percent of Class: 8.759% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 29,238,871 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the CLASS A COMMON STOCK of NUVATION BIO INC. No one other person's interest in the CLASS A COMMON STOCK of NUVATION BIO INC is more than five percent of the total outstanding CLASS A COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the CLASS A COMMON STOCK of NUVATION BIO INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $NUVB alert in real time by email

Recent Analyst Ratings for

$NUVB

Date	Price Target	Rating	Analyst
11/24/2025		Buy	Truist
11/19/2025	$12.00	Buy	B. Riley Securities
9/30/2025	$10.00	Buy	Jefferies
4/23/2025	$6.00	Mkt Outperform	Citizens JMP
3/27/2024	$1.40 → $10.00	Hold → Buy	Jefferies
3/26/2024	$5.00	Neutral → Buy	BTIG Research
1/6/2023	$5.00 → $2.00	Buy → Hold	Jefferies
8/2/2022	$8.00 → $2.50	Outperform → Market Perform	BMO Capital Markets

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

11/12/24 10:32:11 AM ET

$NUVB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NUVB alert in real time by email

Recent Analyst Ratings for

$NUVB

Date	Price Target	Rating	Analyst
11/24/2025		Buy	Truist
11/19/2025	$12.00	Buy	B. Riley Securities
9/30/2025	$10.00	Buy	Jefferies
4/23/2025	$6.00	Mkt Outperform	Citizens JMP
3/27/2024	$1.40 → $10.00	Hold → Buy	Jefferies
3/26/2024	$5.00	Neutral → Buy	BTIG Research
1/6/2023	$5.00 → $2.00	Buy → Hold	Jefferies
8/2/2022	$8.00 → $2.50	Outperform → Market Perform	BMO Capital Markets

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NUVB

Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NUVB

$NUVB
Insider Trading

SEC Form 4 filed by Director Vernon W Anthony

SEC Form 4 filed by Director Mashal Robert

SEC Form 4 filed by Director Falberg Kathryn E

$NUVB
SEC Filings

SEC Form 8-K filed by Nuvation Bio Inc.

SEC Form 8-K filed by Nuvation Bio Inc.

SEC Form 10-Q filed by Nuvation Bio Inc.

$NUVB
Press Releases

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer

$NUVB
Analyst Ratings

Truist initiated coverage on Nuvation Bio

B. Riley Securities initiated coverage on Nuvation Bio with a new price target

Jefferies initiated coverage on Nuvation Bio with a new price target

$NUVB
Insider Purchases

Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

$NUVB
Financials

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

$NUVB
Leadership Updates

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

$NUVB
Large Ownership Changes